- Home
- FNGR vs AVIR Comparison
FNGR vs AVIR Comparison
Compare FNGR & AVIR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FNGR
- AVIR
- Stock Information
- Founded
- FNGR 2016
- AVIR 2012
- Country
- FNGR Singapore
- AVIR United States
- Employees
- FNGR N/A
- AVIR 56
- Industry
- FNGR Computer Software: Prepackaged Software
- AVIR Medicinal Chemicals and Botanical Products
- Sector
- FNGR Technology
- AVIR Health Care
- Exchange
- FNGR Nasdaq
- AVIR Nasdaq
- Market Cap
- FNGR 259.4M
- AVIR 252.5M
- IPO Year
- FNGR N/A
- AVIR 2020
- Fundamental
- Price
- FNGR $3.02
- AVIR $2.97
- Analyst Decision
- FNGR
- AVIR Hold
- Analyst Count
- FNGR 0
- AVIR 1
- Target Price
- FNGR N/A
- AVIR $6.00
- AVG Volume (30 Days)
- FNGR 1.3M
- AVIR 441.1K
- Earning Date
- FNGR 05-29-2025
- AVIR 05-12-2025
- Dividend Yield
- FNGR N/A
- AVIR N/A
- EPS Growth
- FNGR N/A
- AVIR N/A
- EPS
- FNGR N/A
- AVIR N/A
- Revenue
- FNGR $35,607,614.00
- AVIR N/A
- Revenue This Year
- FNGR N/A
- AVIR N/A
- Revenue Next Year
- FNGR N/A
- AVIR N/A
- P/E Ratio
- FNGR N/A
- AVIR N/A
- Revenue Growth
- FNGR N/A
- AVIR N/A
- 52 Week Low
- FNGR $1.03
- AVIR $2.46
- 52 Week High
- FNGR $5.20
- AVIR $4.15
- Technical
- Relative Strength Index (RSI)
- FNGR 46.50
- AVIR 56.05
- Support Level
- FNGR $2.50
- AVIR $2.78
- Resistance Level
- FNGR $4.38
- AVIR $3.03
- Average True Range (ATR)
- FNGR 0.57
- AVIR 0.17
- MACD
- FNGR -0.18
- AVIR 0.03
- Stochastic Oscillator
- FNGR 19.26
- AVIR 88.03
About FNGR FingerMotion Inc.
FingerMotion Inc is engaged in the provision of mobile payment and recharge services in the Chinese market. The company business line includes Telecommunications Products and Services; Value Added Products and Services; Short Message Services (SMS) and Multimedia Messaging Services (MMS); a Rich Communication Services (RCS) platform; Big Data Insights; and a Video Games Division (inactive). It principally earns revenue by providing mobile payment and recharge services to customers of telecommunications companies in China.
About AVIR Atea Pharmaceuticals Inc.
Atea Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing antiviral therapeutics to improve the lives of patients suffering from serious viral infections. The company is developing its product candidate, bemnifosbuvir, for the treatment of COVID-19, the disease caused by infection with Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and its variants and also developing bemnifosbuvir in combination with ruzasvir for the treatment of Hepatitis C (HCV).